A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries

Lancet Infectious Diseases

Volumn 6, Issue 1, 2006, Pages 53-59

  Colebunders, Robert ^a,b,f   Moses, Kamya R ^a   Laurence, John ^a   Shihab, Hasan M ^a   Semitala, Fred ^a   Lutwama, Fred ^a   Bakeera Kitaka, Sabrina ^a   Lynen, Lut ^b   Spacek, Lisa ^c,d   Reynolds, Steven J ^c,d   Quinn, Thomas C ^c,d   Viner, Brant ^e   Mayanja Kizza, Harriet ^a  

^a MAKERERE UNIVERSITY   (Uganda)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CARBAMAZEPINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PHENYTOIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ANAMNESIS; ANOREXIA; ANTIBIOTIC RESISTANCE; CD4 LYMPHOCYTE COUNT; COGNITIVE DEFECT; DEVELOPING COUNTRY; DEVELOPMENTAL DISORDER; DIARRHEA; DRUG EFFICACY; DRUG MONITORING; DRUG QUALITY; DRUG TREATMENT FAILURE; FEVER; GROWTH RETARDATION; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE REACTIVATION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; INFLAMMATION; LABORATORY TEST; LYMPHOCYTE COUNT; MYCOBACTERIOSIS; NEURITIS; OBESITY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURIGO; REVIEW; SYMPTOM; VIRUS INFECTION;

EID: 29244432755     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(05)70327-3     Document Type: Note

References (76)

1. WHO Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2003 revision 2003 WHO Geneva
2. J Stephenson Cheaper HIV drugs for poor nations bring a new challenge: monitoring treatment JAMA 288 2002 151 153
3. N Kumarasamy, TP Flanigan, AP Mahajan, CC Carpenter, KH Mayer, S Solomon Monitoring HIV treatment in the developing world Lancet Infect Dis 2 2002 656 657
4. CJ Smith, S Staszewski, CA Sabin Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals J Acquir Immune Defic Syndr 37 2004 1155 1159
5. JN Nkengasong, C Adje-Toure, PJ Weidle HIV antiretroviral drug resistance in Africa AIDS Rev 6 2004 4 12
6. J Schupbach, J Boni, LR Bisset HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy J Acquir Immune Defic Syndr 33 2003 292 299
7. VL Greengrass, SP Turnbull, J Hocking Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring Curr HIV Res 3 2005 183 190
8. G Stevens, N Rekhviashvili, LE Scott, R Gonin, W Stevens Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa J Clin Microbiol 43 2005 857 861
9. J Schupbach, J Boni, M Flepp, Z Tomasik, H Joller, M Opravil Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: an inexpensive alternative to tests for viral RNA J Med Virol 65 2001 225 232
10. B Ledergerber, M Flepp, J Boni Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparison with viral RNA measurement J Infect Dis 181 2000 1280 1288
11. A Pascual, A Cachafeiro, ML Funk, SA Fiscus Comparison of an assay using signal amplification of the heat-dissociated p24 antigen with the Roche Monitor human immunodeficiency virus RNA assay J Clin Microbiol 40 2002 2472 2475
12. J Braun, JC Plantier, MF Hellot A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes AIDS 17 2003 331 336
13. AJ De Baets, BS Edidi, MJ Kasali Pediatric human immunodeficiency virus screening in an African district hospital Clin Diagn Lab Immunol 12 2005 86 92
14. PL Sharma, V Nurpeisov, B Hernandez-Santiago, T Beltran, RF Schinazi Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase Curr Top Med Chem 4 2004 895 919
15. D Coetzee, K Hildebrand, A Boulle Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa AIDS 18 2004 887 895
16. AD Harries, E Libamba, EJ Schouten, A Mwansambo, FM Salaniponi, R Mpazanje Expanding antiretroviral therapy in Malawi: drawing on the country's experience with tuberculosis BMJ 329 2004 1163 1166
17. C Laurent, C Kouanfack, S Koulla-Shiro Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial Lancet 364 2004 29 34
18. E Florence, J Lundgren, C Dreezen Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study HIV Med 4 2003 255 262
19. HM Lederman, PL Williams, JW Wu Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion J Infect Dis 188 2003 1794 1803
20. L Brigido, R Rodrigues, J Casseb CD4+ T-cell recovery and clinical outcome in HIV-1-infected patients exposed to multiple antiretroviral regimens: partial control of viremia is associated with favorable outcome AIDS Patient Care STDS 18 2004 189 198
21. RW Buckheit Jr Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy Expert Opin Investig Drugs 13 2004 933 958
22. D Wolday, B Hailu, M Girma, E Hailu, E Sanders, AL Fontan Low CD4+ T-cell count and high HIV viral load precede the development of tuberculosis disease in a cohort of HIV-positive Ethiopians Ethiop Med J 41 suppl 1 2003 67 73
23. EF Lyamuya, C Kagoma, EC Mbena Evaluation of the FACScount, TRAx CD4 and Dynabeads methods for CD4 lymphocyte determination J Immunol Methods 195 1996 103 112
24. P Mwaba, S Cassol, R Pilon Use of dried whole blood spots to measure CD4+ lymphocyte counts in HIV-1-infected patients Lancet 362 2003 1459 1460
25. Teav S, Lynen L, Vereecken C, De Munter P, Srey C, Kestens L. Alternative CD4 counting using Cyflow in Cambodia: precision and comparison with Facscount. XV International AIDS Conference; Bangkok, Thailand; July 11-16, 2004
26. Beretta A, Barbesti S, Carcelain G. A simplified flow cytometry of CD4 and CD8 cell counting based on termoresistant reagents: implications for large scale monitoring of HIV infected patients in resource limited settings. 2nd IAS Conference on HIV Pathogenesis and Treatment; Paris, France; July 13-16, 2003
27. J Cohen Monitoring treatment: at what cost? Science 304 2004 1936
28. DM Kent, D McGrath, JP Ioannidis, ML Bennish Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda Clin Infect Dis 37 suppl 1 2003 S13 S24
29. S Diagbouga, C Chazallon, MD Kazatchkine Successful implementation of a low-cost method for enumerating CD4+ T lymphocytes in resource-limited settings: the ANRS 12-26 study AIDS 17 2003 2201 2208
30. R Tilling, S Kinloch, LE Goh Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection AIDS 16 2002 589 596
31. P Ondoa, S Koblavi-Deme, MY Borget, ML Nolan, JN Nkengasong, L Kestens Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Cote d'Ivoire Clin Exp Immunol 140 2005 138 148
32. FA Post, R Wood, G Maartens CD4 and total lymphocyte counts as predictors of HIV disease progression QJM 89 1996 505 508
33. SP Blatt, CR Lucey, CA Butzin, CW Hendrix, DR Lucey Total lymphocyte count as a predictor of absolute CD4+ count and CD4+ percentage in HIV-infected persons JAMA 269 1993 622 626
34. EJ Beck, EJ Kupek, MM Gompels, AJ Pinching Correlation between total and CD4 lymphocyte counts in HIV infection: not making the good an enemy of the not so perfect Int J STD AIDS 7 1996 422 428
35. Y Mekonnen, NH Dukers, E Sanders Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians AIDS 17 2003 815 819
36. MA Jacobson, L Liu, H Khayam-Bashi, SG Deeks, FM Hecht, J Kahn Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy AIDS 17 2003 917 919
37. MR Kamya, FC Semitala, TC Quinn Total lymphocyte count of 1200 is not a sensitive predictor of CD4 lymphocyte count among patients with HIV disease in Kampala, Uganda Afr Health Sci 4 2004 94 101
38. NO Akinola, O Olasode, IA Adediran The search for a predictor of CD4 cell count continues: total lymphocyte count is not a substitute for CD4 cell count in the management of HIV-infected individuals in a resource-limited setting Clin Infect Dis 39 2004 579 581
39. B Lau, SJ Gange, JP Phair, SA Riddler, R Detels, JB Margolick Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection J Acquir Immune Defic Syndr 39 2005 620 625
40. AP Mahajan, JW Hogan, B Snyder Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings J Acquir Immune Defic Syndr 36 2004 567 575
41. M 41 Badri, R Wood Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings AIDS 17 2003 541 545
42. E Florence, W Schrooten, M Van Esbroek The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment. HAART monitoring without viral load Int J STD AIDS 15 2004 538 542
43. T Schreibman, G Friedland Use of total lymphocyte count for monitoring response to antiretroviral therapy Clin Infect Dis 38 2004 257 262
44. SE Buskin, PS Sullivan Anemia and its treatment and outcomes in persons infected with human immunodeficiency virus Transfusion 44 2004 826 832
45. RD Semba, N Shah, RS Klein Highly active antiretroviral therapy associated with improved anemia among HIV-infected women AIDS Patient Care STDS 15 2001 473 480
46. G Moyle, W Sawyer, M Law, J Amin, A Hill Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies Clin Ther 26 2004 92 97
47. M Badri, D Wilson, R Wood Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study Lancet 359 2002 2059 2064
48. CC Hung, SC Chang Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections J Antimicrob Chemother 54 2004 849 853
49. SA Shelburne III, RJ Hamill, MC Rodriguez-Barradas Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy Medicine (Baltimore) 81 2002 213 227
50. Grant A, Fielding K, Charalambous S. Risk factors for early mortality among HIV-infected individuals starting antiretroviral therapy in South Africa. 3rd IAS Conference on HIV Pathogenesis and Treatment; Rio de Janeiro, Brazil; July 24-27, 2005. Abstract MoPe11.6C25.
51. F van Leth, P Phanuphak, K Ruxrungtham Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study Lancet 363 2004 1253 1263
52. R Colebunders, JM Mann, H Francis Generalized papular pruritic eruption in African patients with human immunodeficiency virus infection AIDS 1 1987 117 121
53. Leidner R, Aboulafia D. Flare of AIDS-associated Kaposi's sarcoma (KS) following HAART: a manifestation of immune reconstitution syndrome (IRS). 8th International Conference on Malignancies in AIDS and Other Immunodeficiencies; Bethesda, USA; April 29-30, 2004
54. J Gill, D Bourboulia, J Wilkinson Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma - associated herpesvirus infection in patients with and without Kaposi's sarcoma J Acquir Immune Defic Syndr 31 2002 384 390
55. SH Eshleman, LA Guay, A Mwatha Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012 AIDS Res Hum Retroviruses 20 2004 595 599
56. SH Eshleman, LA Guay, A Mwatha Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012) J Acquir Immune Defic Syndr 35 2004 126 130
57. Johnson J. Resistance emerges in the majority of women provided intrapartum single-dose nevirapine. 12th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 22-25, 2005
58. NE Mackie, S Fidler, N Tamm Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance HIV Med 5 2004 180 184
59. Gallant JE, Rodriguez A, Weinberg W, Young B, Berger D, Lim ML. Early non-response to tenofovir DF + abacavir and lamivudine in a randomized trial compared to efavirenz + abacavir and 3TC: ESS30009 unplanned interim analysis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; Sept 14-17, 2003.
60. H Khanlou, V Yeh, B Guyer, C Farthing Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in treatment naive HIV-infected patients AIDS Patient Care STDS 3 2005 135 140
61. RM Gulick, HJ Ribaudo, CM Shikuma Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection N Engl J Med 350 2004 1850 1861
62. PJ Ruane, E DeJesus New nucleoside/nucleotide backbone options: a review of recent studies J Acquir Immune Defic Syndr 37 2004 S21 S29
63. Moyle G, Maitland D, Hand J, Mandalia S, Nelson M, Gazzard B. Early virological failure in persons with viral loads > 100,000 cps/ml and CD4 counts <200 cells/mm3 receiving ddI/tenofovir/efavirenz as initial therapy: results from a randomized comparative trial. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; Oct 30-Nov 2, 2004. Abstract H-566.
64. D Podzamczer, E Ferrer, JM Gatell, J Niubo, D Dalmau, A Leon Early virological failure and occurrence of resistance in naïve patients receiving tenofovir, didanosine and efavirenz Antivir Ther 9 2004 S172
65. D Back, S Gibbons, S Khoo Pharmacokinetic drug interactions with nevirapine J Acquir Immune Defic Syndr 34 suppl 1 2003 S8 S14
66. S Weiser, W Wolfe, D Bangsberg Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana J Acquir Immune Defic Syndr 34 2003 281 288
67. PJ Weidle, S Malamba, R Mwebaze Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance Lancet 360 2002 34 40
68. DR Bangsberg, FM Hecht, ED Charlebois Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population AIDS 14 2000 357 366
69. DL Paterson, B Potoski, B Capitano Measurement of adherence to antiretroviral medications J Acquir Immune Defic Syndr 31 suppl 3 2002 S103 S106
70. DL Paterson, S Swindells, J Mohr Adherence to protease inhibitor therapy and outcomes in patients with HIV infection Ann Intern Med 133 2000 21 30
71. CF Perno, F Ceccherini-Silberstein, A De Luca Virologic correlates of adherence to antiretroviral medications and therapeutic failure J Acquir Immune Defic Syndr 31 suppl 3 2002 S118 S122
72. N Press, MW Tyndall, E Wood, RS Hogg, JS Montaner Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence J Acquir Immune Defic Syndr 31 suppl 3 2002 S112 S117
73. JC Walsh, S Mandalia, BG Gazzard Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome AIDS 16 2002 269 277
74. JH Oyugi, J Byakika-Tusiime, ED Charlebois Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting J Acquir Immune Defic Syndr 36 2004 1100 1102
75. SG Deeks, R Hoh, TB Neilands Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 Infection J Infect Dis 192 2005 1537 1544
76. SP Koenig, F Leandre, PE Farmer Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience AIDS 18 suppl 3 2004 S21 S25